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Abstract
Background: Smoking and smoking cessation are considered to be associated with weight changes. We have
recently shown that smoking acutely increases plasma levels of ghrelin, a known orexigenic hormone.
Obestatin is a peptide encoded by the ghrelin gene, which opposes ghrelin effects on food intake. We conducted
a study in adult volunteers measuring plasma levels of obestatin immediately after initiation of smoking.
Methods: 31 volunteers (mean age 32.2 ± 9.2 years and mean BMI 25.7 ± 4.1), 17 smokers and 14 non-smokers,
were enrolled in our study. The 2 groups were matched in age and BMI. Plasma obestatin concentrations were
determined at baseline (T0), 2 (T2), 5 (T5), 15 (T15), and 60 (T60) minutes after the initiation of smoking.
Results: In all 31 subjects, no significant difference in the mean values of plasma obestatin levels was observed
from baseline at T2, T5, T15 and T60 after initiation of smoking (overall p = 0.15). However, a trend for higher
obestatin levels was noted in smokers vs non-smokers (overall p = 0.069), which was not related to the pack-years.
Conclusion: On the contrary with ghrelin’s response after smoking initiation, there is no such an acute response of
plasma obestatin levels.
Background
Smoking and smoking cessation are considered to be
associated with weight changes [1]. Weight gain is a pri-
mary reason for not trying to quit smoking. The
mechanism of weight gain includes decreased resting
metabolic rate, increased energy intake, decreased physi-
cal activity and increased lipoprotein lipase activity [2].
We have recently shown that smoking acutely increases
plasma levels of ghrelin, a known orexigenic hormone
[3]. This finding was unexpected in terms of explaining
the known anorectic effect of smoking [1].
Obestatin is a peptide encoded by the ghrelin gene,
which opposes ghrelin effects on food intake [4]. Treat-
ment of rats with obestatin decreased body - weight
gain. We hypothesized that smoking might acutely
increase plasma levels of obestatin in addition to ghrelin
levels. Therefore we conducted a study in adult volun-
teers measuring plasma levels of obestatin immediately
after initiation of smoking.
Methods
Thirty one volunteers, 17 smokers and 14 non smokers,
were enrolled in our study (Table 1). The subjects
received both oral and written information before they
gave their written consent to participate. The study was
approved by the Ethics Committee of the University
Hospital of Alexandroupolis. None of the individuals
had a history of gastric operation or any other serious
health problem. Routine laboratory testing was per-
formed to all of them.
Blood samples were collected after overnight fasting.
After baseline measurements, the participants smoked
one filtered cigarette containing 0.8 mg of nicotine
under standardized conditions: every 15 seconds, a puff
lasting 5 seconds was taken, and the whole cigarette had
to be smoked within 5 minutes. Plasma obestatin con-
centrations were determined at baseline (T0), 2 (T2), 5
(T5), 15 (T15), and 60 (T60) minutes after the initiation
of smoking.
Plasma obestatin levels were measured with a commer-
cial radioimmunoassay (RIA) kit (Phoenix Pharmaceuti-
cals, Belmont, CA) using a 125I-labeled obestatin as a
tracer and a polyclonal antibody rose in rabbits against
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human obestatin. No cross-reactivity was found with
human ghrelin, motilin, leptin or other relevant mole-
cules. All samples were run in duplicate, and mean values
were used for subsequent analysis. The sensitivity of the
assay was 215.5 pg/ml. Intra- and inter-assay coefficients
of variation (CV) reported by the manufacturer were <
5% and < 12% respectively. The linear range was 50-6400
pg/ml. Plasma was frozen in aliquots at -800 C immedi-
ately after centrifugation (40 C, 1600 g for 15 min).
Statistical analysis
The mean values and standard deviation (SD) for the
studied groups were compared using the Student’s t-test
both paired (comparison between 2 groups) and
unpaired (factorial effect on groups). The chi squared
test was used to determine whether a difference existed
between the demographic parameters studied (smoking,
gender). Also simple regression analysis was performed
to check for possible relationships between demographic
parameters and obestatin values. Significance between
groups was set at p = 0.05. Statistical evaluation of the
data was done using StatViewTM 4.5 software (Abacus
Concepts Inc., Berkeley Ca.).
Results
We evaluated the plasma levels of obestatin in 31 sub-
jects, 23 males (74.2%) and 8 females. Demographic
characteristics of all subjects are shown in Table 1. No
significant difference in age was noted between male
and female subjects (p = 0.68) or between smokers and
non smokers (p = 0.54). Also, no significant difference
in BMI was observed between males and females (p =
0.13) and between smokers and non smokers (p = 0.11).
No significant relationship was found between gender
and smoking (chi square = 0.28, p = 0.59), and the
mean pack-years between male (18.4 ± 9.9) and female
(11.2 ± 9.4) smokers was not significant different (p =
0.21).
The mean values of plasma obestatin levels for all 31
patients were at baseline T0 = 148.2 ± 96.8 pg/ml, at 2
minutes T2 = 157.3 ± 133 pg/ml, at 5 minutes T5 =
147.7 ± 100.2 pg/ml, at 15 minutes T15 = 141.6 ± 98.4
pg/ml and at 60 minutes T60 = 127.7 ± 85 pg/ml. No
significant difference was observed from baseline at T2,
T5, T15 and T60 (overall p = 0.15). The mean values
between smokers and non smokers were not significant
different at any time, although there is a trend (overall p
= 0.069) of more acute onset of obestatin levels in smo-
kers, after acute smoking (Figure 1). The increase of
serum levels of obestatin at any time was not related to
the number of pack-years. Also BMI (r2 = 0.32, p =
0.37), or age (r2 = 0.065, p = 0.21) were not factors
influencing the serum levels of obestatin. No significant
difference (p = 0.58) was observed at baseline levels of
obestatin between males (mean: 155.8 ± 90 pg/ml) and
Table 1 Demographic characteristics of all 31 subjects
n Age (years) BMI (kg/m2)
All subjects 31 32.2 ± 9.2 25.7 ± 4.1
Males 23 (74.2%) 31.8 ± 8.8 26.3 ± 3.7
Females 8 (25.8%) 33.3 ± 10.6 23.7 ± 5
Smokers 17 (54.8%) 29.4 ± 7.8 26.7 ± 3.7
Non-smokers 14 (48.2%) 27.4 ± 8.6 24.2 ± 3.7
Values are expressed as mean ± standard deviation (SD).
Figure 1 Effect of smoking on obestatin levels for 17 subjects smokers (red line) and for 14 subjects non-smokers (blue line). Error bars
express standard deviation.
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females (mean: 127.6 ± 118.7 pg/ml) and gender was not
a factor influencing the serum levels of obestatin at any
time (overall p = 0.82).
Discussion
We sought to find if an acute response of obestatin
exists after initiation of smoking similar of that of ghre-
lin [3]. To our knowledge, this is the first study report-
ing results of plasma obestatin after smoking in
volunteers. No acute effect of smoking was noticed.
Taking under consideration the ghrelin increase [3], we
speculate that obestatin does not contribute to the anor-
exic effect of smoking.
Obestatin (a ghrelin-associated peptide) is a 23-amino
acid peptide that is derived from post-translational pro-
cessing of the preproghrelin gene. Mutant mice with a
deletion of the ghrelin gene did not show impaired appe-
tite [5,6] probably because these animals lacked both
orexigenic ghrelin and anorexigenic obestatin. Also in
knockout mice, the lack of the orexigenic signal exerted
by ghrelin may be counterbalanced by the concurrent
absence of the anorexigenic signal exerted by obestatin
[4]. Initially it has been thought that obestatin binds to
the orphan G protein-coupled receptor 39 (GPR39),
although this has been recently questioned [5]. In addi-
tion obestatin has been found to have little or no effect
on pituitary hormone axis, contrary to ghrelin action [6].
Although the difference of obestatin levels between
smokers and non-smokers in our study was not signifi-
cant, we observed a trend for higher levels of obestatin
in smokers when compared with non-smokers. It is
known [7] that ghrelin levels are also higher in smokers
vs non smokers [8], and that these levels are decreased
after smoking cessation [9]. Regarding the relation
between pack-years and obestatin plasma levels in smo-
kers, we did not find any. This is in accordance also
with the findings of Fagerberg et al study [7], where also
ghrelin plasma levels were not associated with cigarette
years.
Serum obestatin levels did not change upon fasting or
feeding in rats [4], but in mice, a slight reduction was
seen upon fasting [10]. In humans also 7 no postpran-
dial changes in serum obestatin levels have been noted
[11]. For a peptide proposed to affect food intake
acutely, this lack of change in circulating concentrations
postprandially is surprising [7]. It is important in the
future to take into account the ratio of ghrelin to obes-
tatin, and not only absolute values of each peptide. This
kind of consideration has been recently used in the eva-
luation of obesity [8], where the ratio of circulating
ghrelin to obestatin was found to be increased. It is pos-
sible, that the increased levels of both ghrelin and obes-
tatin in smokers reflect, at least partially, their different
status of appetite.
In conclusion, our study showed that there is no acute
response of plasma obestatin levels after smoking initia-
tion, although in smokers the levels of plasma obestatin
are higher, but not significantly, comparing to non-
smokers.
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